Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants [Phase 1, Phase 2]
Phase 1/2 study evaluating ASP0739 alone and in combination with pembrolizumab in NY-ESO-1 expressing advanced solid tumors was terminated, …
-
CLINICAL_TRIALS research · 2024-08-06Clinical Trial Update: A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive [Phase 2]
A Phase 2 multicenter randomized trial evaluating an interventional treatment for operable stage II–III non-small cell lung cancer with mini…
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: Food Reward in Cachexia Induced by Acute or Chronic Disease
The clinical trial evaluating food reward as a treatment for cachexia across acute or chronic diseases has been terminated; the conditions i…
-
CLINICAL_TRIALS research · 2024-08-06Clinical Trial Update: Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
Clinical trial update examining perceptions of immunotherapy outcomes in advanced cancer patients with poor performance status, focusing on …
-
CLINICAL_TRIALS research · 2024-08-05Clinical Trial Update: Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance [Phase 2]
A Phase 2 clinical trial is evaluating the combination of osimertinib and abemaciclib in patients with EGFR-mutant non-small cell lung cance…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2024-08-02EMA Withdrawn: Tizveni (tislelizumab) — BeiGene Ireland Ltd
The European Medicines Agency has withdrawn the marketing authorization for Tizveni (tislelizumab) by BeiGene Ireland Ltd for non-small cell…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib [Phase 1, Phase 2]
A completed Phase 1/Phase 2 study evaluating AT13387 in non-small cell lung cancer, both as monotherapy and in combination with crizotinib. …
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study [Phase 2]
Open-phase 2 multicenter trial evaluating Milaberon in advanced solid tumors across multiple indications, currently recruiting.
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment
This clinical trial update notes an ongoing study from Ruijin Hospital assessing surgical strategies for patients with non-small cell lung c…
-
EMA approval · 2024-07-31EMA Authorised: Taxotere (docetaxel) — Sanofi Winthrop Industrie
The EMA authorised Taxotere (docetaxel) for multiple cancer indications including head and neck cancer, non-small cell lung cancer, gastric …
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer [Phase 1]
Phase 1 trial evaluating the combination of ramucirumab and pembrolizumab in gastric/GEJ adenocarcinoma, non-small cell lung cancer, urothel…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating Surufatinib alone or in combination with Vinorelbine for advanced Non-Small Cell Lung Cancer; current trial status …
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
The Galileo Project is a longitudinal study investigating genomic alterations and clonal evolution in ALK-positive non-small cell lung cance…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma [Phase 2]
Phase 2 trial evaluating adjuvant Benmelstobart for Stage IB, Grade 3 invasive lung adenocarcinoma (non-small cell lung cancer) is currently…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery [Phase 2]
Phase 2 study evaluating Osimertinib in patients with EGFR-mutated non-small cell lung cancer who progressed after adjuvant targeted therapy…
-
EMA withdrawal · 2024-07-30EMA Withdrawn: Pemetrexed Krka (pemetrexed disodium) — KRKA d.d.
EMA has withdrawn the product Pemetrexed Krka (pemetrexed disodium) from the market.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy [Phase 2]
Phase 2 study of cisplatin plus pemetrexed and bevacizumab as first-line therapy for non-small cell lung cancer has been terminated with res…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors [Phase 2]
A Phase 2 trial evaluating Cediranib in combination with Olaparib in advanced solid tumors has posted results as of 2024-07-30. Indications …
-
CLINICAL_TRIALS research · 2024-07-30Clinical Trial Update: A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients [Phase 2]
A Phase II trial evaluating SSGJ-707 in combination therapy for first-line, advanced non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2024-07-30Clinical Trial Update: From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.
Clinical trial update describing the potential role of endobronchial fiducial markers in guiding surgical resection of ground-glass lung nod…
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study of PF-07209960 in advanced or metastatic solid tumors was terminated, with results posted in July 2024.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer [Phase 2]
A Phase 2 clinical trial registry entry evaluating the combination of glumetinib and albumin-bound docetaxel versus docetaxel alone for MET-…
-
CLINICAL_TRIALS research · 2024-07-26Clinical Trial Update: High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib [Phase 2]
A Phase 2 clinical trial evaluating high-dose furmonertinib for advanced, metastatic non-small cell lung cancer in patients who progressed a…
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]
First-in-human Phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer has been completed.
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: Prognostic Significance of the Uncertain Resection in NSCLC
Update on a clinical trial assessing how uncertain resection affects prognosis in non-small cell lung cancer; the study is currently active …